Evidence map›Paper›PMID 33460239›Full record

ArticleJournal of cellular and molecular medicine2020

lncRNA MIR4435-2HG promoted clear cell renal cell carcinoma malignant progression via miR-513a-5p/KLF6 axis.

Kai Zhu, Chenkui Miao, Ye Tian, Zhiqiang Qin, Jianxin Xue, Jiadong Xia, Shenhao Zhu, Aiming Xu, Jie Yang, Zengjun Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kai ZhuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0002-4096-7975
Chenkui MiaoDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ye TianDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhiqiang QinDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jianxin XueDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiadong XiaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shenhao ZhuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Aiming XuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie YangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zengjun WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0002-7583-4750
Jiangsu Province Hospital · CNNanjing University of Chinese Medicine · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) take various biological effects in clear cell renal cell carcinoma (ccRCC) mostly through sponging with microRNAs (miRNAs). lncRNA MIR4435-2HG is found to promote tumour progression in gastric cancer, glioblastoma and hepatocellular carcinoma. However, the role of lncRNA MIR4435-2HG in ccRCC progression remains unknown. The purpose of this research was to investigate the potential molecular mechanism of lncRNA MIR4435-2HG regarding the regulation of ccRCC initiation and progression. In this study, we found the up-regulation of MIR4435-2HG in ccRCC tissues and cell lines. Functionally, overexpression of MIR4435-2HG promoted the proliferation as well as the metastasis in ccRCC cell lines, whereas knockdown of MIR4435-2HG inhibited the above changes. Then, bioinformatic analysis and luciferase reporter assays confirmed the negative regulation effect of MIR4435-2HG on miR-513a-5p. And further investigations showed that KLF6, which collected from the intersection of databases, was the potential conjugated mRNAs of miR-513a-5p. Finally, the rescue experiments revealed the relation among MIR4435-2HG and KLF6, which showed that KLF6 could reverse the promoting effect of MIR4435-2HG on ccRCC in vitro and in vivo. Therefore, our findings provided insight into the mechanisms of MIR4435-2HG in ccRCC and revealed an alternative target for the clinical diagnosis and treatment of ccRCC.

Indexed as

AnimalsCarcinoma, Renal CellCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansKidney NeoplasmsKruppel-Like Factor 6MaleMice, Inbred BALB CMice, NudeMicroRNAsMiddle AgedKLF6 protein, humanKruppel-Like Factor 6MicroRNAsMIRN513A1 microRNA, humanRNA, Long NoncodingccRCCinvasionKLF6long non‐coding RNAMIR4435‐2HGproliferation

Identifiers

PMID33460239
PMCPMC7520272
OpenAlexW3046633324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.